Novartis (NVS) Given “Neutral” Rating at Deutsche Bank

Deutsche Bank reiterated their neutral rating on shares of Novartis (NYSE:NVS) in a report released on Friday.

Several other research firms have also recently weighed in on NVS. JPMorgan Chase reissued a neutral rating on shares of Novartis in a research note on Thursday, January 18th. UBS reissued a neutral rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research cut shares of Novartis from a hold rating to a sell rating in a research note on Tuesday, January 2nd. Finally, Nord/LB reissued a neutral rating on shares of Novartis in a research note on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $87.51.

How to Become a New Pot Stock Millionaire

NVS stock traded down $1.12 during mid-day trading on Friday, reaching $77.88. The company’s stock had a trading volume of 2,925,246 shares, compared to its average volume of 1,893,218. The company has a market cap of $183,079.03, a price-to-earnings ratio of 16.19, a PEG ratio of 1.79 and a beta of 0.74. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. Novartis has a fifty-two week low of $73.31 and a fifty-two week high of $94.19.



Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, April 19th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.03. Novartis had a net margin of 16.04% and a return on equity of 16.18%. The business had revenue of $12.69 billion during the quarter, compared to analysts’ expectations of $12.45 billion. During the same quarter in the prior year, the company posted $1.13 EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. equities analysts forecast that Novartis will post 5.28 earnings per share for the current year.

Several large investors have recently bought and sold shares of the stock. Garland Capital Management Inc. boosted its position in shares of Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock worth $4,385,000 after purchasing an additional 535 shares during the period. Tradition Capital Management LLC boosted its position in shares of Novartis by 0.9% during the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock worth $5,825,000 after purchasing an additional 652 shares during the period. Commerce Bank boosted its position in shares of Novartis by 2.4% during the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock worth $2,352,000 after purchasing an additional 664 shares during the period. West Oak Capital LLC boosted its position in shares of Novartis by 4.4% during the 4th quarter. West Oak Capital LLC now owns 15,860 shares of the company’s stock worth $1,332,000 after purchasing an additional 665 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Novartis by 1.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,425 shares of the company’s stock worth $3,814,000 after purchasing an additional 716 shares during the period. 10.76% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Novartis (NVS) Given “Neutral” Rating at Deutsche Bank” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://stocknewstimes.com/2018/04/21/novartis-nvs-given-neutral-rating-at-deutsche-bank.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply